(VNDA) Vanda Pharmaceuticals - Ratings and Ratios
Antipsychotic, Sleep
VNDA EPS (Earnings per Share)
VNDA Revenue
Description: VNDA Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs worldwide. The company has a diverse portfolio of marketed products, including HETLIOZ for non-24-hour sleep-wake disorders, Fanapt for bipolar I disorder and schizophrenia, and a pipeline of products in various stages of development.
The companys pipeline includes several promising candidates, such as Tradipitant for gastroparesis and atopic dermatitis, Imsidolimab for generalized pustular psoriasis, and VTR-297 for hematologic malignancies. Additionally, Vanda has a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors, as well as antisense oligonucleotide molecules for various indications, including Charcot-Marie-Tooth Disease and polycythemia vera.
From a financial perspective, Vanda Pharmaceuticals has a market capitalization of $288.19M USD, with a forward P/E ratio of 30.30. The companys return on equity (RoE) is currently negative at -8.30%, indicating that it is not generating profits. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and cash burn rate. The companys cash position and funding strategy will be crucial in supporting its pipeline development and commercialization efforts.
To evaluate the potential of Vanda Pharmaceuticals, its essential to monitor the progress of its pipeline products, particularly those in late-stage development. The companys ability to successfully commercialize its marketed products and bring new products to market will be critical in driving revenue growth and improving profitability. Additionally, investors should keep an eye on the competitive landscape and any potential partnerships or collaborations that could impact the companys prospects.
VNDA Stock Overview
| Market Cap in USD | 266m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2006-04-12 |
VNDA Stock Ratings
| Growth Rating | -62.4% |
| Fundamental | 16.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -26.1% |
| Analyst Rating | 4.0 of 5 |
VNDA Dividends
Currently no dividends paidVNDA Growth Ratios
| Growth Correlation 3m | -36.7% |
| Growth Correlation 12m | -36% |
| Growth Correlation 5y | -86.7% |
| CAGR 5y | -23.63% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.43 |
| Sharpe Ratio 12m | -2.58 |
| Alpha | 0.03 |
| Beta | 0.938 |
| Volatility | 46.23% |
| Current Volume | 304k |
| Average Volume 20d | 340.4k |
| Stop Loss | 4.2 (-5.8%) |
| Signal | 0.36 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-66.9m TTM) > 0 and > 6% of Revenue (6% = 12.2m TTM) |
| FCFTA -0.03 (>2.0%) and ΔFCFTA -4.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 134.4% (prev 189.8%; Δ -55.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.10 (>3.0%) and CFO -64.8m > Net Income -66.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.0m) change vs 12m ago 1.33% (target <= -2.0% for YES) |
| Gross Margin 93.54% (prev 90.95%; Δ 2.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.89% (prev 27.94%; Δ 3.94pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -1.01
| (A) 0.44 = (Total Current Assets 394.9m - Total Current Liabilities 121.5m) / Total Assets 624.7m |
| (B) -0.37 = Retained Earnings (Balance) -231.0m / Total Assets 624.7m |
| (C) -0.14 = EBIT TTM -88.3m / Avg Total Assets 638.1m |
| (D) -1.67 = Book Value of Equity -230.5m / Total Liabilities 138.4m |
| Total Rating: -1.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 16.69
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -43.38% = -5.0 |
| 3. FCF Margin -7.99% = -2.99 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.27 = -2.50 |
| 6. ROIC - WACC (= -26.72)% = -12.50 |
| 7. RoE -12.89% = -2.15 |
| 8. Rev. Trend -38.62% = -2.90 |
| 9. EPS Trend -85.43% = -4.27 |
What is the price of VNDA shares?
Over the past week, the price has changed by -1.11%, over one month by -2.19%, over three months by -2.62% and over the past year by -12.20%.
Is Vanda Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VNDA is around 3.21 USD . This means that VNDA is currently overvalued and has a potential downside of -28.03%.
Is VNDA a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VNDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.7 | 184.1% |
| Analysts Target Price | 12.7 | 184.1% |
| ValueRay Target Price | 3.6 | -18.8% |
Last update: 2025-09-11 04:52
VNDA Fundamental Data Overview
CCE Cash And Equivalents = 325.6m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 90.9091
P/S = 1.3098
P/B = 0.5528
P/EG = -2.42
Beta = 0.739
Revenue TTM = 203.5m USD
EBIT TTM = -88.3m USD
EBITDA TTM = -81.3m USD
Long Term Debt = 16.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.68m USD (from shortTermDebt, last quarter)
Debt = 21.6m USD (Calculated: Short Term 4.68m + Long Term 16.9m)
Net Debt = -69.3m USD (from netDebt column, last quarter)
Enterprise Value = -37.5m USD (266.5m + Debt 21.6m - CCE 325.6m)
Interest Coverage Ratio = unknown (Ebit TTM -88.3m / Interest Expense TTM 0.0)
FCF Yield = -43.38% (FCF TTM -16.2m / Enterprise Value -37.5m)
FCF Margin = -7.99% (FCF TTM -16.2m / Revenue TTM 203.5m)
Net Margin = -32.90% (Net Income TTM -66.9m / Revenue TTM 203.5m)
Gross Margin = 93.54% ((Revenue TTM 203.5m - Cost of Revenue TTM 13.1m) / Revenue TTM)
Tobins Q-Ratio = 0.16 (Enterprise Value -37.5m / Book Value Of Equity -230.5m)
Interest Expense / Debt = 16.31% (Interest Expense 3.52m / Debt 21.6m)
Taxrate = 21.0% (US default)
NOPAT = -88.3m (EBIT -88.3m, no tax applied on loss)
Current Ratio = 3.25 (Total Current Assets 394.9m / Total Current Liabilities 121.5m)
Debt / Equity = 0.04 (Debt 21.6m / last Quarter total Stockholder Equity 486.3m)
Debt / EBITDA = -0.27 (Net Debt -69.3m / EBITDA -81.3m)
Debt / FCF = -1.33 (Debt 21.6m / FCF TTM -16.2m)
Total Stockholder Equity = 519.4m (last 4 quarters mean)
RoA = -10.71% (Net Income -66.9m, Total Assets 624.7m )
RoE = -12.89% (Net Income TTM -66.9m / Total Stockholder Equity 519.4m)
RoCE = -16.46% (Ebit -88.3m / (Equity 519.4m + L.T.Debt 16.9m))
RoIC = -16.99% (NOPAT -88.3m / Invested Capital 519.4m)
WACC = 9.73% (E(266.5m)/V(288.1m) * Re(9.47%)) + (D(21.6m)/V(288.1m) * Rd(16.31%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 0.32%
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -16.2m)
EPS Correlation: -85.43 | EPS CAGR: -59.40% | SUE: -1.17 | # QB: 0
Revenue Correlation: -38.62 | Revenue CAGR: -7.58%
Additional Sources for VNDA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle